Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRENX LTD.BNRG · Entity 8475 | Director | March 18, 2026 | March 18, 2026 |
| Microbot Medical Inc.MBOT · Entity 6767 | Director · Chairman, President and CEO | February 18, 2026 | February 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRENX LTD.
Report date March 18, 2026 · Filed March 18, 2026
This filing explicitly reported no securities owned.
Microbot Medical Inc.
Report date February 18, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2036-02-18 | Direct | 480,000 |
Reported balance
After 2026-02-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-18 · Grant · Acquired 480,000 · Balance 480,000 F1: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 20, 2026 21:45 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 480,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001493152-26-007612 · ownership.xml · derivative · entry 1 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,000 Underlying: Common Stock, par value $0.01 per share · 480,000 shares Expires 2036-02-18 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 228,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001493152-25-005407 · ownership.xml · derivative · entry 1 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,000 Underlying: Common Stock, par value $0.01 per share · 228,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 5, 2025, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| February 26, 2024 Filed Feb 26, 2024 23:41 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 79,567 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001493152-24-007871 · ownership.xml · derivative · entry 3 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,567 Underlying: Common Stock, par value $0.01 per share · 79,567 shares Expires 2034-02-26 Read SEC document |
| February 26, 2024 Filed Feb 7, 2025 21:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001493152-25-005407 · ownership.xml · derivative · entry 2 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock, par value $0.01 per share · 12,000 shares Expires 2034-02-26 F2 · date: Such options, granted on February 26, 2024, were performance-based options the vesting of which was subject to the satisfaction of milestones. On February 5, 2025, the Compensation Committee of the Board of Directors of the Issuer confirmed and determined that the milestones with respect to 12,000 options have been met and, accordingly, vested. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 23:41 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001493152-24-007871 · ownership.xml · derivative · entry 2 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock, par value $0.01 per share · 80,000 shares Expires 2034-02-22 Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 23:41 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001493152-24-007871 · ownership.xml · derivative · entry 1 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock, par value $0.01 per share · 80,000 shares Expires 2034-02-22 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 22, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001493152-23-026630 · ownership.xml · derivative · entry 1 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock, par value $0.01 per share · 80,000 shares Expires 2033-08-01 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on February 1, 2024, the options shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| December 21, 2022 Filed Jan 9, 2023 11:03 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001493152-23-000874 · ownership.xml · derivative · entry 1 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock, par value $0.01 per share · 160,000 shares Expires 2032-12-21 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on June 21, 2023, the options shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001493152-22-002551 · ownership.xml · derivative · entry 1 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock, par value $0.01 per share · 100,000 shares Expires 2032-01-26 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on July 26, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:15 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $8.48 | $0.00 |
DisclosureSEC source: 0001493152-21-002536 · ownership.xml · derivative · entry 1 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock, par value $0.01 per share · 190,000 shares Expires 2031-02-01 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on February 1, 2022, the options shall vest and shall become exercisable with respect to 50% of the common stock; and (b) on a quarterly basis thereafter over the following year, the option shall equally vest and become exercisable with respect to the remaining 50% of the common stock. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:00 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 166,666 | $0.00 Strike: $9.64 | $0.00 |
DisclosureSEC source: 0001493152-20-003083 · ownership.xml · derivative · entry 1 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,666 Underlying: Common Stock, par value $0.01 per share · 166,666 shares Expires 2030-02-25 Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 12:36 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock, par value $0.01 per share | 40,000 | $10.00 | $400,000.00 |
DisclosureSEC source: 0001493152-19-019697 · ownership.xml · nonDerivative · entry 1 Gadot Harel · CIK 0001690103 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By MEDX Ventures Group, LLC Disclosed balance after: 136,847 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in April 2019. F2 · balance_after: Does not include any options to purchase common stock owned by the reporting person. F3 · ownership.nature: Mr. Gadot is the Chief Executive Officer, Company Group Chairman and majority equity owner of MEDX Venture Group and thus may be deemed to share voting and investment power over the shares beneficially owned by this entity. Read SEC document |
| September 14, 2017 Filed Sep 18, 2017 20:59 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 476,190 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001493152-17-010718 · form4.xml · derivative · entry 2 Gadot Harel · CIK 0001690103 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,190 Underlying: Common Stock, par value $0.01 per share · 476,190 shares Expires 2027-09-14 F2 · derivative.exercise_date: The options vest equally on an annual basis over 60 months commencing on the one year anniversary of the date of grant, and in accordance with the terms of the Issuer's Equity Incentive Plan. Read SEC document |
| September 14, 2017 Filed Sep 18, 2017 20:59 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 1,336,522 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001493152-17-010718 · form4.xml · derivative · entry 1 Gadot Harel · CIK 0001690103 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,336,522 Underlying: Common Stock, par value $0.01 per share · 1,336,522 shares Expires 2027-09-14 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's Equity Incentive Plan: (a) on the six month anniversary of the date of grant, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.